Market Signal Briefing

Bitcoin May Tank to $100K as Friday’s BTC Crash Reinforced 2017–21 Trendline ResistanceBitcoin's recent crash marks the third failure to maintain gains above a critical trendline from 2017 and 2021 highs. Oct 13, 2025, 4:26 a.m.

This is a daily analysis by CoinDesk analyst and Chartered Market Technician Omkar Godbole.

We've probably all heard this phrase: "Once is an accident, twice is a coincidence, three times is a pattern."

STORY CONTINUES BELOW

The old saying is perfectly applicable to the bitcoin BTC$114,763.67 market, where the crash on Friday marked the third time bulls failed to maintain gains above the critical trendline drawn from the 2017 and 2021 highs, raising the possibility of a deeper drop to $100,000 or lower.

This repeated inability to hold above that level highlights a persistent resistance, suggesting that the trendline is now a key battleground likely defining the limits of the bullish strength in this cycle. CoinDesk highlighted the trendline resistance a month ago, noting that bulls had twice failed to maintain gains above it.

BTC's monthly chart in candlestick format. (TradingView)

The long wicks on the July, August, and October candles signal bull fatigue above the trendline.

At the same time, the MACD histogram on the monthly chart – although still positive – is lower than it was during the December-January rally when BTC first broke above $100,000, indicating a weakening of upward momentum. MACD, a moving average-based indicator, is widely used to identify trend changes and trend strength.

The daily chart below also paints a bearish picture.

BTC's daily chart. (TradingView)

The sharp reversal from the expanding channel resistance, combined with negative readings in both the standard (12, 26, 9) and longer-term (50, 100, 9) MACD histograms, signals that the path of least resistance is downward.

The longer duration histogram, which uses 50- and 100-day EMAs and a 9-day EMA to smooth the signal, is significantly slower and less sensitive than the default setting, but better suited for filtering out short-term market noise.

Taken together, the monthly and daily charts suggest scope for a drop to sub-$100K levels, marking a test of the lower end of the expanding triangle. On the way lower, the 200-day simple moving average at $107,000 could also offer support.

Bulls will need to engineer a break above $121,800 to invalidate the series of lower highs and overturn the bearish outlook. At press time, BTC changed hands at $114,800, according to CoinDesk data.

More For You

Total Crypto Trading Volume Hits Yearly High of $9.72T

Sep 9, 2025

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025

What to know:

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025Gate exchange emerged as major player with 98.9% volume surge to $746 billion, overtaking Bitget to become fourth-largest platformOpen interest across centralized derivatives exchanges rose 4.92% to $187 billionView Full Report

More For You

Dogecoin Zooms 11% as DOGE Buying Volumes Quadruples

8 minutes ago

The pattern shows an ascending trendline with constructive momentum; MACD and RSI signals remain bullish.

What to know:

Dogecoin surged 11% in 24 hours, driven by institutional inflows and increased trading volume.

Traders are monitoring if Dogecoin can maintain a close above $0.22 to target further gains.

The rally coincided with a broader recovery in meme-coins and increased professional market activity.

Read full story

The race to launch the first spot XRP exchange-traded fund (ETF) has entered a decisive phase even as the crypto market faces steep losses. On October 10, the U.S. Securities and Exchange Commission (SEC) received a new set of S-1/A amendment filings for proposed XRP ETFs from 21Shares, Bitwise, Franklin Templeton, WisdomTree, Grayscale, and Canary Capital.

21Shares Files CME-Linked XRP ETFThe latest filing from 21Shares outlines a fund designed to track XRP’s price using the CME CF XRP-Dollar Reference Rate (XRPUSD_NY), a recognized benchmark used by institutional investors.

The ETF will be organized as a Delaware trust and will hold XRP in cold storage with Coinbase Custody Trust Company. Shares will list on the Cboe BZX Exchange, giving investors exposure to XRP through regular brokerage accounts.

The filing confirms the ETF will be passive, with no use of leverage or derivatives. Authorized Participants will create or redeem shares in exchange for cash or XRP based on the CME benchmark. The document also notes the product carries high risk and lacks FDIC insurance or Investment Company Act protections.

SEC Introduces Faster ETF Listing RulesRecent regulatory updates could speed up ETF approvals. For the first time, the SEC’s new generic ETF listing standards allow exchanges like Nasdaq, Cboe, and NYSE to list spot crypto ETFs without separate case-by-case approval.

Previously, applications often took more than 240 days to process. The new rules could cut that to 60–75 days, a big change for issuers waiting in line.

Crypto analyst Diana said that 21Shares and Canary have revised their filings to meet updated standards. Changes include:

Clearer custody and redemption procedures
Stronger surveillance-sharing agreements
Full alignment with SEC feedback
“These updates are the kind of cleanup you do right before launch,” she wrote on X.

Launch Could Come in Early 2026

If the SEC stays on its current track, XRP ETFs could debut soon. The first issuer to meet the criteria will move ahead under the new fast-track process.

The next steps include:

Acknowledgment letters confirming receipt
Exchange listing notices under new rules
Effective S-1 status
Any conditional approvals that may follow
Uncertainty remains. The SEC could still delay decisions, especially given political tensions and the recent government shutdown.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

BNB price staged an impressive comeback on Monday, Oct. 13, rebounding 16% in the past 24 hours to trade around $1,309 at press time.

Summary

BNB price surged 16% to $1,309, leading recovery after the Oct. 10 market crash.
CZ refuted claims of Binance or affiliates supporting the token.
Rising spot and futures volumes suggest growing trader confidence.

The recovery follows one of the market’s sharpest flash crashes in recent history, during which the total crypto market cap fell by more than $500 billion in a single day. Despite that drop, BNB has held up better than most top altcoins, now up 11% over the past week and 41% in the past month.

With confidence restored, trading activity has surged. BNB’s (BNB) 24-hour spot volume increased 50.2% to $8.94 billion. Similar momentum was seen in the derivatives markets. CoinGlass data shows that open interest increased 29.8% to $2.42 billion and futures volume rose 98.5% to $11.63 billion.

The jump in open interest alongside volume suggests traders are re-entering positions rather than simply exiting short-term bets, a bullish sign that the market is regaining confidence.

CZ addresses BNB price rebound amid speculation
As speculation swirled about potential intervention behind BNB’s rapid recovery, Binance founder Changpeng Zhao clarified on X that neither he nor any affiliated entities had participated in recent trading activity.

“Many projects have a market maker. BNB doesn’t,” CZ wrote. “I am not aware of any of my affiliated entities buying or selling BNB in the past days or weeks.”

He emphasized that BNB’s strength comes from its builders, community, and deflationary tokenomics rather than artificial support. CZ’s statement followed rumors that Binance might have stepped in to stabilize the market following the Oct. 10 crash, which erased nearly $19 billion in leveraged positions.

Analysts and traders praised BNB for its resilience in the wake of the incident, with one analyst calling it a “flight-to-safety” token. BNB’s decline was only about 10% before it quickly recovered, compared to other popular altcoins that saw drops of 15% to 50%. 

BNB price technical analysis
Following the weekend crash, BNB’s chart displays a strong V-shaped recovery, and the token is currently trading well above its mid-Bollinger Band support at $1,124. There is still potential for an upward push, as indicated by the relative strength index at 65, which shows increasing bullish momentum but not yet overbought conditions.

BNB daily chart. Credit: crypto.news
BNB may retest its upper Bollinger Band around $1,370, which also acts as immediate resistance, if buying pressure is sustained. Its wider uptrend, which started in late August, might continue if there is a breakout above this level, which would open the path toward $1,450–$1,500. 

On the downside, key support lies between $1,100 and $1,150, where bulls are likely to defend against another correction.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

After the Friday crash, which saw one of the biggest liquidations in history, the crypto market has staged a strong recovery with Bitcoin price reclaiming $115,000 as of press time. Altcoins led by Ethereum have staged a strong recovery, gaining 10-20% each. ETH, BNB, XRP, SOL, and DOGE are all up as market experts, like Raoul Pal, predict a V-Shape recovery.

Crypto Market Will See V-Shaped Rebound, Says Raoul Pal
Macro investor and Real Vision CEO Raoul Pal described Friday’s market turmoil as a “Flash Crash.” He noted that such events typically recover quickly in a V-shaped rebound. Funding rates in the crypto market crashed to their lowest since the 2022 bear market, marking one of the most severe leverage resets in crypto history.

Pal stated that the sell-off is characteristic of prior flash crashes that soon reclaimed their previous price ranges and often went on to make new highs. “In this case, we entirely wiped out all accumulated leverage too,” Pal said, adding that the next move for the market is likely “higher.”

One common underlying message that most experts have for retail investors is avoiding excessive leverage and greed. Experts have been advising to take learnings from the crypto market crash and build on spot positions instead of leveraged ones.

In his message on the X platform, Pillows noted: “Coinbase Bitcoin premium is going up. Some heavy institutional buying is happening now”.

Rising Bitcoin premium index shows institutional buying
100% Trump Tariff Fears on China Are Waning
Market sentiment improved sharply after the odds of the U.S. imposing 100% tariffs on China fell to just 17%, as per the Polymarket data. This clearly signals a potential easing in trade.  tensions.

Source: Polymarket
On the other hand, US President Donald Trump has also softened his stand, fueling a rebound across financial markets, including the crypto market. Analysts noted that the shift in rhetoric comes at a crucial time for traders. This will restore confidence and spark renewed buying interest across risk assets. In his message on Truth Social, Donald Trump wrote:

“Don’t worry about China, it will all be fine! Highly respected President Xi just had a bad moment. He doesn’t want Depression for his country, and neither do I. The U.S.A. wants to help China, not hurt it!!! “

Bitcoin Leads Crypto Market Recovery, Altcoins Rally
Bitcoin price has bounced back above $115,000 levels again, as of press time, with daily trading volumes over $91 billion. Amid this market turmoil, Strategy Chairman Michael Saylor hinted at buying the BTC dips with his message “Don’t stop Believing”.

Don’t Stop ₿elievin’ pic.twitter.com/LUMroqLSCl

— Michael Saylor (@saylor) October 12, 2025

On the other hand, Ethereum (ETH) is leading the altcoin market recovery with 10% and shooting past $4,100. XRP was among the first major altcoins to rebound following the recent market crash, with more than $30 billion flowing back into the asset, according to Cryptos Rus. The quick recovery signals that traders view the downturn as temporary rather than structural.

BNB price has surged the most with 15% upside in the last 24 hours, and regained $1,300 once again. Analysts see Binance coin rally continuing to reach fresh all-time highs.

Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.

Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.

Solana started a fresh increase above the $180 zone. SOL price is now consolidating above $185 and might aim for more gains above the $200 zone.

SOL price started a fresh upward move above the $175 and $180 levels against the US Dollar.
The price is now trading below $200 and the 100-hourly simple moving average.
There is a bullish trend line forming with support at $188 on the hourly chart of the SOL/USD pair (data source from Kraken).
The pair could extend gains if it clears the $200 resistance zone.

Solana Price Eyes More Gains
Solana price started a decent increase after it found support near the $155 zone, beating Bitcoin and Ethereum. SOL climbed above the $172 level to enter a short-term positive zone.

The price even smashed the $180 resistance. The bulls were able to push the price above the 50% Fib retracement level of the downward move from the $225 swing high to the $155 low. Besides, there is a bullish trend line forming with support at $188 on the hourly chart of the SOL/USD pair.

Solana is now trading below $200 and the 100-hourly simple moving average. On the upside, the price is facing resistance near the $198 level and the 61.8% Fib retracement level of the downward move from the $225 swing high to the $155 low. The next major resistance is near the $200 level.

Source: SOLUSD on TradingView.com
The main resistance could be $205. A successful close above the $205 resistance zone could set the pace for another steady increase. The next key resistance is $212. Any more gains might send the price toward the $220 level.

Another Decline In SOL?
If SOL fails to rise above the $200 resistance, it could start another decline. Initial support on the downside is near the $190 zone and the trend line. The first major support is near the $182 level.

A break below the $182 level might send the price toward the $175 support zone. If there is a close below the $175 support, the price could decline toward the $160 support in the near term.

Technical Indicators

Hourly MACD – The MACD for SOL/USD is gaining pace in the bullish zone.

Hourly Hours RSI (Relative Strength Index) – The RSI for SOL/USD is above the 50 level.

Major Support Levels – $188 and $182.

Major Resistance Levels – $198 and $200.

After months of quiet trading, Dash (DASH) has made a powerful comeback. The digital currency surged from around $20 in late September to over $56 this week, marking its highest level since December 2024.

This recovery comes even as the broader market remains choppy — with Bitcoin hovering near $122,500 and the total crypto market capitalization around $4.23 trillion, down roughly 1% week-over-week.

The rally has renewed attention on Dash’s fundamentals and its unique place in the payments-focused corner of the crypto market.

Built on a Strong FoundationLaunched in 2014 by developer Evan Duffield, Dash — originally short for “Digital Cash” — was designed for fast, low-cost, and private payments. The network uses a hybrid model of Proof-of-Work mining and masternodes, which enable advanced features like:

InstantSend, for near-instant transactions, andPrivateSend, for optional transaction privacy.Dash’s block reward structure helps sustain its ecosystem:

45% to miners,45% to masternodes, and10% to the Dash DAO treasury.This self-funding model has kept Dash’s development continuous, even during quieter market cycles, reinforcing its position as a long-term, community-governed project.

Technical Breakout Confirms Bullish MomentumAccording to market data, Dash recently broke out of a five-year descending wedge pattern, signaling a potential shift toward a broader uptrend.

After consolidating between $17.70 and $26.25, Dash entered the markup phase described in Wyckoff’s Market Cycle Theory. It now trades well above its 50-day and 100-day Exponential Moving Averages (EMAs) and has reached the 50% Fibonacci retracement level, technical signs that bulls are firmly in control.

Analysts note that a short-term pullback toward $35 is possible to confirm support, but the medium-term structure remains bullish, with $70 as the next key resistance.

DASH Pay Adoption and Renewed Network InterestPart of Dash’s resurgence can be linked to renewed enthusiasm around DASH Pay, the network’s payment ecosystem that emphasizes usability and speed.

Year-to-date, Dash is up nearly 96%, including an 80% surge in the past month. Traders who held through the summer accumulation phase are now realizing significant returns.

Community sentiment has also improved as masternode activity remains steady, indicating long-term network confidence and continued governance participation.

Comparison: Dash vs. Other Payment CryptosWhile projects like Litecoin (LTC) and Bitcoin Cash (BCH) continue to dominate payment-layer discussions, Dash’s governance structure and privacy options give it distinct advantages.

Unlike many newer projects, Dash maintains a fully decentralized treasury, which funds ongoing development and community initiatives without reliance on external investors — a key factor in its long-term sustainability.

What’s Next for Dash in 2025?With its latest breakout, analysts are watching for catalysts that could sustain Dash’s momentum into 2025

Integration with major payment processors or merchant platforms,Upgrades to the Dash Platform that enhance user experience, andRenewed exchange listings as liquidity returns to older projects.Some technical analysts forecast a potential range of $70–$100 if bullish momentum continues, though they caution that long-term upside depends on network growth and real-world adoption.

Key Support and Resistance Levels (as of October 13, 2025)LevelTypeDescription$35SupportLikely pullback zone if short-term correction occurs$50Resistance-turned-supportBreakout level; key for bulls to defend$70Next resistanceAligned with Dec 2024 highs$100Long-term targetBased on 61.8% Fibonacci extensionMarket Outlook SummaryIndicatorCurrent ReadingTrend50-day EMA$42Bullish100-day EMA$38BullishRSI (Daily)67Slightly overboughtMarket SentimentPositiveModerate bullish biasFAQsIs Dash still a good investment in 2025?

Dash remains a respected project with a strong technical foundation and governance model. While volatility persists, it continues to attract investors seeking utility-driven cryptocurrencies.

What is the Dash price prediction for 2025?

Analysts currently forecast potential targets between $70 and $100, assuming broader market strength and increased adoption of Dash payments.

How does the Dash DAO work?

The Dash DAO allocates 10% of each block reward to a treasury system that funds development, marketing, and community proposals — voted on by masternode operators.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

A trader who attracted attention for successfully shorting Bitcoin (CRYPTO: BTC) just before the recent crash added to their position even as the market rebounded on Sunday.

Investor Doubles Down On Bearish PositionThe investor opened the position at $117,369 and was sitting on an unrealized profit of $3.70 million as of this writing, according to decentralized perpetual exchange Hyperliquid. The trader took a 10x leverage bet to boost the position's value to over $163 million.

If Bitcoin reaches $123,510, which is 7.59% away from its current price, the trader will be liquidated.

Interestingly, the bet was taken despite the market’s sharp rebound, with Bitcoin regaining $115,000 on Sunday.

See Also: Bitcoin (BTC) Price Predictions: 2025, 2026, 2030

Signs Of Insider Trading?The whale grabbed headlines after opening multi-million dollar short positions on BTC and Ethereum (CRYPTO: ETH) right before President Donald Trump threatened to impose 100% tariffs on China.

The cryptocurrency market tumbled in response and the trader subsequently closed most of their short positions, netting a profit of $160 million.

Reacting to the development, capital markets commentator The Kobeissi Letter said, "Did Someone Know?"

This is not the first time that suspicions of insider trading have been raised in relation to Trump’s posts.

Earlier in March, a trader opened a 50x leveraged bet on Bitcoin and Ethereum shortly before Trump announced a cryptocurrency reserve, turning an investment of $4 million into a $200 million position.

Price Action: At the time of writing, BTC was exchanging hands at $114,716.93, up 2.59% in the last 24 hours, according to data from Benzinga Pro.

Read Next: 

Bitcoin’s Flash Crash Over Weekend Prompts Analyst To Sound Warning on BTC ETFs: Continuous Liquidity Essential To ‘Prudent Risk Management’
Photo Courtesy: Yalcin Sonat On Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The 'Uptober' sentiment might have been dented but 'perhaps not derailed,' said one analyst, with BTC and ETH rebounding.

“ETF inflows remain strong, exchange balances near cycle lows, and the broader narrative is arguably stronger after the washout,” one analyst said.Updated Oct 13, 2025, 6:03 a.m. Published Oct 13, 2025, 5:50 a.m.

Bitcoin BTC$114,864.70 traders are catching their breath after one of the wildest weekends in the asset’s history.

The flash crash that happened late Friday following Trump’s 100% tariff announcement on Chinese imports wiped nearly $19 billion in crypto positions — the largest single-day liquidation on record.

STORY CONTINUES BELOW

But some 48 hours later, the market looks steadier, with a bounce taking shape as both Washington and Beijing moved to cool tensions.

Alternative cryptocurrencies such as ADA$0.7007 and DOGE$0.2075 are leading the bounce. Both SDA aand DOGE have gained nearly 10% in 24 hours as discounted valuations enticed bargain hunters.

Bitcoin BTC$114,864.70 climbed 2.7% over the past 24 hours to about $114,665, while ether ETH$3,818.39 surged 8.3% to $4,135. BNB gained 13.9%, a reminder that liquidity is flowing back toward ecosystem tokens. XRP rose 7.4%, Solana SOL$194.03 added 7.2%.

The market’s message is clear: the broader bullish trend hasn’t broken, but the volatility has reset sentiment.

“What we just saw was a massive emotional reset,” said Justin d’Anethan, head of partnerships at Arctic Digital.

“Volatility cuts both ways — traders were punished on the way down and on the snap back. But the longer-term structure is intact. ETF inflows remain strong, exchange balances near cycle lows, and the broader narrative is arguably stronger after the washout,” he added.

That washout was no small thing. Over 6,300 wallets were liquidated on decentralized exchange Hyperliquid alone, with some traders losing millions in a cascade triggered by Auto-Deleveraging — a circuit-breaker that closes winning positions to cover systemic losses when insurance funds run dry.

It stopped bad debt, but it also magnified the fall, turning the correction into a structural event.

U.S.-China tensions easeThe rebound began over the weekend when China’s Ministry of Commerce clarified that rare-earth export controls wouldn’t be a blanket ban, while Trump himself posted that “the U.S.A wants to help China, not hurt it.”

Markets took that as a sign the trade war rhetoric was cooling, and risk assets bounced accordingly.

At this stage, crypto is moving in step with macro again. “If the U.S.–China spat doesn’t escalate into a full-on trade war, the market is likely to recover and push back toward all-time highs,” said Jeff Mei, COO at BTSE, in a note to CoinDesk.

The path ahead will hinge on rates and risk appetite. If central banks lean into easing, traders expect ETH and yield-generating tokens to outperform. Funding rates, options skew, and whale flows will show where fresh capital rotates next.

The setup is volatile, but the conviction remains. I’d say the shakeout burned leverage, not belief.

More For You

Total Crypto Trading Volume Hits Yearly High of $9.72T

Sep 9, 2025

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025

What to know:

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025Gate exchange emerged as major player with 98.9% volume surge to $746 billion, overtaking Bitget to become fourth-largest platformOpen interest across centralized derivatives exchanges rose 4.92% to $187 billionView Full Report

More For You

BTC Mining Firm Marathon (MARA) Scoops Up 400 BTC After Price Crash, On-Chain Data Show

16 minutes ago

Arkham data shows bitcoin miner Marathon bought 150 BTC through its custodian Anchorage Digital as prices plunged, with fresh FalconX inflows hinting at continued institutional accumulation.

What to know:

Marathon Digital Holdings increased its bitcoin holdings by purchasing an additional 400 BTC valued at approximately $45.9 million.Bitcoin experienced a significant drop of nearly 13% due to U.S.–China tariff tensions, but has since recovered slightly.Analysts warn that bitcoin's inability to maintain gains above key resistance levels may lead to a retest of $100,000.Read full story

Arkham data shows bitcoin miner Marathon bought 150 BTC through its custodian Anchorage Digital as prices plunged, with fresh FalconX inflows hinting at continued institutional accumulation.
Oct 13, 2025, 5:55 a.m.

Marathon Digital Holdings (NASDAQ: MARA) appears to have taken advantage of Friday's market turmoil to load up on bitcoin BTC$114,729.41, according to data curated by Arkham Intelligence.

Marathon Digital Holdings, which holds about 52,850 BTC (worth roughly $6.06 billion), purchased an additional 400 BTC valued at about $45.9 million through FalconX early Monday, according to Arkham Intelligence data tracked by blockchain sleuth Lookonchain.

STORY CONTINUES BELOW

MARA's move suggests that corporates and miners are once again accumulating BTC into volatility, similar to the patterns seen in prior market resets. The miner produced 218 blocks in September, a 5% increase over August, as global hashrate grew 9% month-over-month to an average of 1,031 EH/s.

CoinDesk reached out to MARA for official confirmation.

Bitcoin plunged nearly 13% within an hour on Friday after renewed U.S.–China tariff threats sparked a global risk-off wave, wiping out about $65 billion in open interest, although some market stakeholders suggest the real culprit in the crash was Binance, with internal errors causing assets to de-peg.

At the time of writing, bitcoin traded near $114,800, up about 3% in the past 24 hours as trade-war tensions ease between Washington and Beijing.

BTC’s failure to sustain gains above the long-term resistance trendline from the 2017 and 2021 highs could open the door to a retest of $100,000, according to CoinDesk analysts.

More For You

Total Crypto Trading Volume Hits Yearly High of $9.72T

Sep 9, 2025

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025

What to know:

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025Gate exchange emerged as major player with 98.9% volume surge to $746 billion, overtaking Bitget to become fourth-largest platformOpen interest across centralized derivatives exchanges rose 4.92% to $187 billionView Full Report

More For You

Dogecoin Zooms 11% as DOGE Buying Volumes Quadruples

20 minutes ago

The pattern shows an ascending trendline with constructive momentum; MACD and RSI signals remain bullish.

What to know:

Dogecoin surged 11% in 24 hours, driven by institutional inflows and increased trading volume.

Traders are monitoring if Dogecoin can maintain a close above $0.22 to target further gains.

The rally coincided with a broader recovery in meme-coins and increased professional market activity.

Read full story

The Bitcoin price was gradually coiling up, eyeing $130,000, and forming consecutive higher highs and lows. The rally paused when US President Donald Trump reignited trade tensions with China by imposing 100% tariffs on select goods. This triggered a sharp market sell-off, leading to over $20 billion in liquidations within hours. Now that the President has signaled a willingness to negotiate, the BTC price is witnessing a measured recovery.

Institutional interest in Bitcoin continues to grow, with Trump’s own company reportedly accumulating BTC alongside giants like MicroStrategy and MetaPlanet. Since then, Bitcoin’s price action has steadied, avoiding another single-day crash. As US political and economic dynamics evolve, Bitcoin appears closely tethered to these shifts—leaving investors to wonder: Is it time to trust the recovery and invest in Bitcoin now?

Behind the Crash: What Really Triggered Bitcoin’s Sudden Fall?While the US–China tariff tension served as the official spark, several on-chain and trading patterns suggest that the recent Bitcoin and crypto market crash may have had deeper roots. Analysts point to a series of suspicious moves that indicate the sell-off could have been strategically orchestrated rather than purely reactionary.

Whale Activity Before the Drop: Blockchain trackers flagged a Satoshi-era wallet that reportedly opened a $1.1 billion short position hours before the tariff announcement. This timing has fueled strong speculation that some large players anticipated the news in advance.Exchange Mechanics & Forced Liquidations: The crash triggered over $20 billion in liquidations, exposing the vulnerability of highly leveraged traders. Some suggest exchanges may have let liquidation cascades run deep to flush overleveraged positions.Insider-Like Trading Patterns: The simultaneous surge in short open interest across major derivatives platforms points toward coordinated market positioning—a move more typical of insiders than retail participants.Despite the theories, none of these claims are proven. Yet, they highlight a critical reality—Bitcoin’s price remains heavily influenced by powerful hands and centralized liquidity flows, not just global headlines. 

Can Bitcoin (BTC) Price Sustain Recovery Toward $130K?The crypto markets faced one of the largest liquidations last week, which has changed the trade dynamics for the BTC price for a while. The token quickly dropped heavily, breaking the critical support zone between $119,850 and $120,600. The ascending support did its job well and prevented the price from excessively bearish action. However, it would be interesting to witness how the recovery will unfold hereafter, as the bullish action remains a little vague at the moment. 

As seen in the above chart, the BTC price remains within a bullish trajectory regardless of the recent market crash. The price is trading between the 50-day & the 200-day MA which has been acting as the interim resistance & support level. Although the RSI has triggered a rebound, it quickly displayed a bearish divergence before rising beyond the average range. This suggests the indecisiveness among the bulls, which may further compel the price to drop back to the local support. 

Wrapping it Up!No doubt the Bitcoin bulls prevented the price from plunging below the psychological barrier at $100K, but the recovery has also been challenged by the bears. Since August, the price has been struggling to hold strongly above $117,000 which has now become one of the important zones to secure. Moreover, the latest rise above this zone also resulted in a market crash which brings us to the conclusion that the investors need to watch out closely before investing in Bitcoin at the moment.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

The crypto market has seen a rollercoaster week, but prices are finally bouncing back. Bitcoin has climbed more than 4% in the past 24 hours, trading around $114,662, while Ethereum surged over 10% to $4,133.

The rebound followed Donald Trump’s recent statement aimed at easing global worries about the U.S.-China trade tensions.

 “We don’t want to hurt China, we want to work with them,” Trump said

After a sharp sell-off hit both stock and crypto markets earlier this week.

Trump Becomes the Largest Bitcoin Whale Donald Trump has emerged as one of the largest Bitcoin holders in the world. According to Forbes, Trump indirectly owns about $870 million worth of Bitcoin through his 41% stake in Trump Media & Technology Group, the parent company of Truth Social.

Earlier this year, Trump Media made headlines by investing $2 billion in Bitcoin, using funds raised from stock and debt sales. The move echoes MicroStrategy’s Bitcoin investment strategy, led by Michael Saylor. Despite recent market volatility, Trump Media’s Bitcoin holdings have become its strongest-performing asset, signaling growing confidence in digital currencies.

From Bitcoin Critic to SupporterTrump’s views on Bitcoin have changed dramatically over time. Back in 2019, he criticized it as “highly volatile” and “based on thin air.” But today, he has taken a completely different tone.

Since returning to the office, Trump has voiced support for blockchain innovation in the U.S., pushing policies designed to make the country a leader in crypto development. His administration recently introduced the GENIUS Act, aimed at boosting research and development in blockchain and digital asset technologies.

With Trump’s growing influence in crypto and whales making bold moves, the market faces a critical moment. Will Bitcoin continue its upward trend, or is another correction on the horizon?

For now, all eyes remain on Trump’s next statements and the broader crypto market recovery after trade war fears.

Never Miss a Beat in the Crypto World!Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: I am not an investment advisor, and this article is not meant to be a recommendation for the purchase or sale of stock. Investors are advised to review all company documents and press releases to see if the company fits its own investment qualifications.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quanex Building Products Corporation (NYSE: NX) between December 12, 2024 and September 5, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Quanex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Quanex’s procedures and policies regarding tooling and equipment maintenance in its Tyman Mexico facility were significantly “underinvested”; (2) as a result, Quanex’s tooling and equipment conditions had significantly degraded to near “catastrophic” levels; (3) as a result of the foregoing, Quanex was likely to incur significant costs, “pushing out the timing” of expected benefits from the Tyman integration; (4) Quanex had previously identified the foregoing issues; and (5) as a result of the foregoing, defendants’ positive statements about Quanex’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Palantir's frothy valuation isn't for everyone.

Palantir Technologies has been one of the most dynamic -- and controversial -- stocks in the market for the last couple of years. Palantir's extraordinary run includes a 2,130% gain over the last three years. Had you invested $10,000 into Palantir stock then, you'd be sitting on a nest egg of $223,000 (at the time of this writing).

While the data mining company's growth is impressive and it has its bulls -- including me -- the stock's valuation is admittedly out of hand. Palantir stock has a trailing price-to-earnings (P/E) ratio of an eyewatering 623, and a forward P/E of 217. The price-to-sales (P/S) ratio is hard to stomach as well, coming in at 137.

I'm a believer in the Palantir growth story, and I've long said that the market doesn't yet recognize the stock's true potential. But Palantir's not for everyone. If you're looking for some outstanding artificial intelligence (AI) stocks that don't carry the baggage that Palantir sports, here are two to consider right now.

Image source: Getty Images.

1. Advanced Micro Devices
Advanced Micro Devices (AMD -7.78%) is seen as second fiddle to the biggest chipmaker in the bunch, Nvidia. But it's quietly having a better year. AMD stock is up 90% so far this year, compared to Nvidia's 43% gain.

A huge percentage of that gain has been this month, after AMD and OpenAI announced a deal that would see the maker of ChatGPT purchase 6 gigawatts of AMD's Instinct MI450 graphics processing units (GPUs) to power several generations of OpenAI infrastructure. AMD issued a warrant that allows OpenAI to buy up to 160 million shares of stock, which could mean a 10% stake in the company.

Wedbush analyst Dan Ives, who is one of the most well-known analysts covering the AI and tech space, called the deal a "huge vote of confidence" for AMD.

"With a 10% stake in AMD, this quickly brings ... [AMD CEO] Lisa Su and AMD right into the core of the AI chip spending cycle and is a huge vote of confidence from OpenAI and ... [OpenAI CEO Sam] Altman. Any lingering fears around AMD should now be thrown out the window," he wrote in a social media post. "Major validation moment for AMD."

He's right. OpenAI is a huge player in the AI space, and its partnership with AMD is an endorsement of the company's GPUs. Even though Nvidia has the lion's share of the market, AMD now has an opportunity. And it's cheap, compared to Palantir, with a trailing P/E of 101 and a forward P/E of 28.5.

2. CoreWeave
However, GPUs are only half the story. Companies also need the horsepower to run AI applications, delivered at scale. And that's where CoreWeave (CRWV -3.32%) comes in.

CoreWeave is a cloud computing company that rents its Nvidia-supplied GPUs and cloud infrastructure to companies and developers who are working on AI and machine learning projects. Microsoft has been CoreWeave's biggest client, accounting for 62% of its revenue in 2024. Nvidia is also a key partner, holding 24.3 million shares, and CoreWeave also has $22.4 billion in deals with OpenAI.

The fast-growing company has 33 data centers across the country, with a revenue backlog of $30.1 billion, up 86% from a year ago. The company's revenue in the second quarter was $1.21 billion, up from $395.3 million a year ago. "We are scaling rapidly as we look to meet the unprecedented demand for AI," CEO Michael Intrator said.

CoreWeave isn't making a profit yet, but the company's growth is impressive. The stock is up 250% so far this year, and its forward price-to-sales ratio of 13 is much more palatable than Palantir's 104.4.

The bottom line
I still like Palantir and am holding my position. But not every AI stock investor is OK with a nosebleed premium, so AMD and CoreWeave are compelling alternatives. AMD has been validated as a key AI player, and CoreWeave is building infrastructure and making high-quality AI capacity widely available. Together, they are a great way to invest in AI.

Patrick Sanders has positions in Nvidia and Palantir Technologies. The Motley Fool has positions in and recommends Advanced Micro Devices, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies

October 13, 2025 00:00 ET

 | Source:

HUTCHMED (China) Limited

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announces results from the FRUSICA-2 registration clinical trial of the fruquintinib and sintilimab combination for the treatment of patients with locally advanced or metastatic renal cell carcinoma. Results of the Phase III part of the study will be presented on Friday, October 17, 2025 during the European Society for Medical Oncology (“ESMO”) Congress in Berlin, Germany.

FRUSICA-2 is a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced renal cell carcinoma (NCT05522231). A total of 234 patients were randomized into a group that received fruquintinib plus sintilimab combination therapy, or into a group that received axitinib or everolimus monotherapy. As of the progression free survival (“PFS”) final analysis cutoff of February 17, 2025, the median follow-up was 16.6 months.

The median PFS as assessed by blinded independent central review (BICR) was 22.2 months with fruquintinib plus sintilimab, compared to 6.9 months with axitinib/everolimus (stratified hazard ratio [HR] 0.373; stratified log-rank p<0.0001). The objective response rate (ORR) was 60.5% vs 24.3% (Odds Ratio 4.622, p<0.0001), and the median duration of response (DoR) was 23.7 vs 11.3 months, respectively. Overall survival data were still evolving at the time of data cutoff with maturity of approximately 20%. Efficacy benefits were observed in all prognostic risk groups, as defined by the International mRCC Database Consortium (IMDC) criteria.

The safety profile of the fruquintinib and sintilimab combination was tolerable and consistent with the known profiles of each individual treatment. Treatment-emergent adverse events (TEAEs) of grade 3 or above occurred in 71.4% of patients in the fruquintinib plus sintilimab group compared to 58.8% for patients in the axitinib/everolimus group.

“The FRUSICA-2 trial results provide compelling evidence that fruquintinib and sintilimab may offer a valuable new treatment option for patients with advanced renal cell carcinoma,” said Professor Dingwei Ye of Fudan University Shanghai Cancer Center and the co-leading Principal Investigator of the FRUSICA-2 study. “These findings show the combination’s potential to address a critical unmet need for this patient population, delivering consistent benefits across varied patient profiles and prognostic risk groups.”

“The FRUSICA-2 study suggests that fruquintinib and sintilimab could play a meaningful role in shaping second-line treatment strategies for advanced renal cell carcinoma,” said Professor Zhisong He of Peking University First Hospital and the co-leading Principal Investigator of the FRUSICA-2 study. “These results point to the combination’s potential to enhance clinical outcomes, providing a new option for managing this challenging disease.”

Supported by data from FRUSICA-2, a New Drug Application (NDA) for the combination of fruquintinib and sintilimab in patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment has been accepted for review by the China National Medical Products Administration (NMPA).

About Kidney Cancer and Renal Cell Carcinoma
It is estimated that approximately 435,000 new patients were diagnosed with kidney cancer worldwide in 2022.1 In China, an estimated 74,000 new patients were diagnosed with kidney cancer in 2022.2 Approximately 90% of kidney tumors are renal cell carcinoma.

The safety and efficacy of fruquintinib for the investigational uses discussed above have not been established and there is no guarantee that it will receive health authority approval or become commercially available in any country for the uses being investigated.

About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. VEGFR inhibitors play a pivotal role in inhibiting tumor angiogenesis. Fruquintinib was designed to limit off-target kinase activity and improve drug exposure to achieve sustained target inhibition.3

Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®.  It is approved for the treatment of patients with metastatic colorectal cancer who have previously received fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy, and those who have previously received or are not suitable to receive anti-VEGF therapy or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type) in China. The combination of fruquintinib and sintilimab has received conditional approval in China for the treatment of patients with advanced pMMR endometrial cancer who have failed prior systemic therapy and are not candidates for curative surgery or radiation.

Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.

About HUTCHMED
HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, the further clinical development for fruquintinib, its expectations as to whether any studies on fruquintinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries+852 2121 8200 / [email protected]  Media Enquiries FTI Consulting –+44 20 3727 1030 / [email protected] Atwell / Alex Shaw+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Brunswick – Zhou Yi+852 9783 6894 (Mobile) / [email protected]  Panmure LiberumNominated Advisor and Joint BrokerAtholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500  CavendishJoint BrokerGeoff Nash / Nigel Birks+44 20 7220 0500  Deutsche NumisJoint BrokerFreddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000   ____________________________
1   The Global Cancer Observatory, kidney cancer fact sheet. https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf. Accessed February 19, 2025.
2   The Global Cancer Observatory, China fact sheet. https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf. Accessed February 19, 2025.
3   Sun Q, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. doi: 10.4161/15384047.2014.964087.

Empowering insurers with smart automation and AI to modernize operations, enhance decision-making, and drive growth

, /PRNewswire/ - DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced the launch of DXC Assure Smart Apps, a new suite of AI-powered, workflow-driven applications designed to transform how insurers engage with customers, brokers, and advisors. Built for speed, precision, and flexibility, Assure Smart Apps combine intelligent automation with modular innovation to help insurers modernize operations and improve performance, all while leveraging existing systems.

DXC Launches Assure Smart Apps to Accelerate AI-Driven Innovation in the Insurance Industry (CNW Group/DXC Technology Services, LLC)

As insurers look to adopt AI and accelerate growth while managing costs and complexity, DXC Assure Smart Apps help insurers implement AI-driven solutions efficiently. The suite fully integrates with insurers' core systems through industry-leading cloud capabilities powered by Amazon Web Services (AWS), and APIs of the DXC Assure Platform. Enabling insurers to leverage AI and natural language processing while maintaining their core systems, Assure Smart Apps built with DXC's Assure BPM delivers seamless workflow orchestration, enterprise scalability, and rapid deployment.

"Assure Smart Apps meet insurers where they are, whether they're maintaining heritage systems, extending capabilities, or transforming for the future," said Ray August, President of Insurance Software and Business Process Services at DXC. "This launch represents a major leap forward in how insurers digitize and automate every step of their business processes. Our modular approach provides the flexibility to innovate at their own pace, without disrupting critical operations or existing investments."

Assure Smart Apps are purpose-built with features to address today's most common insurance challenges facing brokers, customers, and advisors:

Self-service capabilities: Allows customers, brokers, and advisors to make their own updates on the platform and change information as needed.
Customer support: Equips customers with personal insurance concierge accessible from their mobile device, using AI-driven insights to provide real-time support.
AI insights: AI-enabled dashboards draw from previously arranged contracts to generate intelligent insights and speed up the decision-making process.
Leverage existing systems: Assure Smart Apps can be built and deployed quickly, working with existing DXC solutions to minimize disruption.
DXC's partnership with ServiceNow enhances the Assure BPM platform's workflow technology and agentic AI capabilities, ensuring robust performance, scalability, and an approximate 80% reduction in process design time. Smart Apps can be implemented individually or bundled into Smart Solutions—market-ready offerings tailored to specific business needs.

With over 40 years of industry expertise, DXC is a trusted partner of choice for 21 of the top 25 insurers. As a leading provider of core insurance systems, DXC continues to innovate—helping insurers accelerate revenue while reducing complexity and costs across more than 1 billion policies processed on DXC software. 

For more information on DXC's insurance solutions, visit our website.

About DXC Technology
DXC Technology (NYSE: DXC) is a leading global provider of information technology services. We're a trusted operating partner to many of the world's most innovative organizations, building solutions that move industries and companies forward. Our engineering, consulting and technology experts help clients simplify, optimize and modernize their systems and processes, manage their most critical workloads, integrate AI-powered intelligence into their operations, and put security and trust at the forefront. Learn more on dxc.com. 

ServiceNow, the ServiceNow logo, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries.

SOURCE DXC Technology Services, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

There is a lot of hype with this quantum computing company. But it has a lot of bark and little bite.

Everyone wants to own quantum computing stocks. Companies like IonQ (NYSE: IONQ) are up hundreds of percent in the last year, with the aforementioned stock now at a market cap of $25 billion while generating less than $100 million in revenue. Quantum computing could drive huge gains in productivity if the technology is ever commercialized, but today, IonQ is a highly speculative company with little to no business model. This makes it an incredibly risky stock to own.

Here are two stocks not betting on a speculative science fiction future, but creating value in the present. Both Remitly Global (RELY -3.13%) and Portillo's (PTLO -2.76%) will be larger than IonQ in five years' time. Here's why you should add them to your portfolio over any quantum computing stock.

Remitly's disruptive opportunity
Remitly Global has moved in the opposite direction from IonQ in 2025. Shares of the remittance provider are off 42% from highs set earlier in 2025, while IonQ is up 78% year to date (YTD) and just reached a new all-time high.

Investors are nervous about Remitly because of the immigration crackdown in the United States, which may reduce cross-border payments from the United States to Mexico and other Latin American countries. This is Remitly's core business as a mobile disruptor to the legacy players, such as Western Union. Fears are also rising due to a new tax on remittance payments, although it is just a 1% tax and likely not to greatly impact payment flows.

Despite these worries, Remitly has posted strong growth throughout 2025. Revenue was up 34% year over year last quarter, with 40% growth in send volume. Not only is Remitly completely disregarding immigration fears for remittance demand, but it is also taking a ton of market share from legacy players due to its low fees and easy-to-use mobile application.

What's more, Remitly is starting to get profitable. On $1.46 billion in trailing revenue, the business generated an earnings before interest and taxes (EBIT) of $27 million, with plenty of room to increase its operating leverage over time. Compare that to IonQ with minimal revenue and huge operating losses, and Remitly looks like a company that should have a larger market cap than any quantum computing stock.

Image source: Getty Images.

Portillo's expansion plans
Portillo's is a restaurant chain that sells Chicago-style street food, such as hot dogs and Italian beef sandwiches. It has begun to expand to other markets such as Texas and Florida with average success, as some of its restaurant volumes have been hit by a broad slowdown in consumer spending at restaurants in 2024 and 2025.

Despite this, Portillo's is poised to grow substantially in the years ahead. It is planning to slowly grow its presence in new states around the country, bringing this beloved Chicago brand to a national stage. Last quarter, Portillo's posted just 3.6% annual revenue growth, but that is due to the fact that its new store openings are going to be weighted to the back half of 2025. With the company planning to have just around 100 restaurant locations at the end of this year, there is still a huge runway for the concept to expand to new metropolitan areas in the United States.

Portillo's has a market cap of just $464 million today. Investors may look at this market capitalization compared to IonQ and think it is impossible for the restaurant operator to surpass the $25 billion stock within five years. But let's truly compare the underlying financials to show why IonQ is grossly overvalued at its current price.

Over the last 12 months, Portillo's generated $65 million in EBIT on $728 million in revenue. IonQ generated just $53 million in revenue and lost $351 million (it has never been profitable). Portillo's may not surpass a $25 billion market cap in five years, but it will be larger than IonQ because IonQ does not deserve anything close to a $25 billion valuation.

Buy Remitly and Portillo's. Avoid IonQ and other quantum computing stocks. Your portfolio will thank you five years from now.

Brett Schafer has positions in Remitly Global. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Asian markets had a rocky start to the week as fresh Trump tariff threats rekindled worries about a U.S.-China trade war, sparking a selloff across regional indexes.

The brands people consume year-round can make excellent income investments.

Some of the best income investments are the stocks of brands people buy every day in the grocery store. People have been drinking Coca-Cola (KO 1.02%) and eating Hershey (HSY -0.19%) chocolate for over 100 years, and that's not likely going to change. Here's why these top dividend stocks are solid buys right now.

Image source: Getty Images.

1. Coca-Cola
Coca-Cola owns a large portfolio of beverage brands that generate consistent revenue and profits, which fund growing dividend payments. Despite economic hurdles with inflation and choppy consumer spending trends over the past few years, the stock has returned 21% over the last three years and currently offers an attractive forward dividend yield of 3%.

People are not going to stop consuming orange juice, water, coffee, tea, energy beverages, and carbonated soft drinks. Coca-Cola owns top brands across all these categories. This provides opportunities across different occasions to generate sales.

Coca-Cola reported a 1% decline in unit case volume last quarter, reflecting the weak consumer spending trends it has dealt with recently. But higher selling prices drove a 5% year-over-year increase in adjusted (non-GAAP) revenue.

Its strong brands generate healthy margins that support the dividend. Coca-Cola generated $12 billion in net income on $47 billion of revenue over the last year. Through the first half of 2025, it paid out over $2.2 billion in dividends. Its full-year payout ratio is typically around 75% of earnings per share.

After increasing its quarterly dividend by 5% in March to $0.51, Coca-Cola has now increased its dividend for 63 consecutive years -- a testament to the strength of its brands and business strategy.

Investors can expect Coca-Cola to grow its adjusted earnings per share around 8% annually over the long term, which is consistent with management's goal. Combining this earnings growth with a 3% yield should put the total annualized return around 11%.

2. Hershey
Record-high cocoa prices and the recent tariffs on cocoa imports have hurt Hershey's earnings and stock performance. However, with the stock trading 29% below its previous peak (at the time of this writing) and offering a high yield, this is a great time to build a position.

Despite higher operating costs, Hershey is still profitable. Management cited healthy momentum in the business, with adjusted net sales (excluding currency changes) up 26% year over year. While adjusted earnings were down 5%, the company generated $1.6 billion in free cash flow and paid 65% of that in dividends over the last year.

In addition to its namesake brand, Hershey owns several recognizable candy brands like Twizzlers and Reese's. It has also expanded into snacks like Skinny Pop. Management noted that solid execution at driving sales is leading to market share gains in the U.S. confectionery and salty snacks markets.

Spikes in commodity prices have a way of working themselves out in the long run. But even with those higher costs, management has taken steps to mitigate higher commodity costs by raising prices and improving efficiency in the business. This will allow the business to emerge more profitable down the road once cocoa prices settle.

With cocoa prices recently coming down, this could be a great time to buy shares. The quarterly dividend is $1.37, bringing the forward yield to 2.85%. It has rarely offered a yield this high in the last 30 years.

Wall Street analysts believe Hershey will never grow earnings again, but this shows recency bias with recent headwinds and is unrealistic for this iconic chocolate brand. The stock may remain volatile in the near term, but investors should expect the business to continue paying dividends and rewarding shareholders for potentially decades to come.

John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hershey. The Motley Fool has a disclosure policy.

October 13, 2025 01:00 ET

 | Source:

F. Hoffmann-La Roche Ltd

Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held 17-21 October 2025 in Berlin, Germany. The data underscore Roche’s commitment to deliver transformative medicines for some of the most challenging cancer types, including breast cancers, lung cancers, gastrointestinal and genitourinary cancers.

Key presentations include:

Giredestrant: Primary results from the phase III evERA Breast Cancer study, the first positive head-to-head phase III trial investigating a selective oestrogen receptor (ER) degrader-containing regimen versus a standard of care combination in the post-cyclin-dependent kinase inhibitor setting for people with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.1,2 The study met both co-primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival in both the intention-to-treat and ESR1-mutated populations.3 Data will be presented as a late-breaking oral abstract. Tecentriq: Results from the IMvigor011 trial, the first global phase III study pioneering a circulating tumour DNA (ctDNA)-guided approach to post-surgery treatment in muscle-invasive bladder cancer (MIBC).4 Topline results show that people who had detectable ctDNA and were treated with Tecentriq® (atezolizumab) had statistically significant and clinically meaningful improvements in disease-free survival (DFS) and overall survival (OS).5 Data will be presented as part of the Presidential Symposium.Alecensa: Final OS data from the pivotal ALEX study of Alecensa® (alectinib).6 Alecensa is an established first-line treatment and a standard of care for people with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).7-9 Data will be presented as a late-breaking oral abstract and published simultaneously in the Annals of Oncology.Alecensa: Updated results from the phase III ALINA study, reinforcing the role of adjuvant Alecensa as the standard of care for patients with resected ALK-positive NSCLC.10 After a median follow-up of approximately four years, Alecensa DFS data compared with chemotherapy will be presented.10 Overview of key presentations featuring Roche medicines:

Medicine Abstract title Abstract number/presentation details Breast cancer Giredestrant Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial #LBA16 late-breaking oral Proffered paper session 1: Breast cancer, metastatic

Saturday 18 October 2025

10:15-10:25 CEST

Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): the EMPRESS study (IIS: MEDSIR)* #294MO mini oral Mini oral session: Breast cancer, early stage

Sunday 19 October 2025

10:50-10:55 CEST

Giredestrant plus Itovebi™ (inavolisib) Interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (rx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC) #508P poster Poster session: Breast cancer, metastatic

Monday 20 October 2025

12:00-17:30 CEST

Itovebi™ phase I/Ib trial of inavolisib (INAVO) + pertuzumab (P) + trastuzumab (H) for
PIK3CA-mutated (mut), HER2-positive advanced breast cancer (HER2+ aBC) #548P poster Poster session: Breast cancer, metastatic

Monday 20 October 2025

12:00-17:30 CEST

Genitourinary cancer Tecentriq® (atezolizumab) IMvigor011: a phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer #LBA8 late-breaking oral Presidential Symposium III

Monday 20 October 2025

16:30-16:42 CEST

Lung cancer Alecensa® (alectinib) Final overall survival (OS) and safety analysis of the phase III ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC) #LBA73 late-breaking oral Proffered paper session: NSCLC metastatic

Friday 17 October 2025

17:06-17:16 CEST

Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC) #1787MO mini oral Mini oral session 2: Non-metastatic NSCLC

Monday 20 October 2025

14:50-14:55 CEST

Tecentriq Patterns of disease progression (PD) and efficacy associated with tumour burden from
the phase III IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L)
maintenance treatment (tx) in ES-SCLC #2762MO mini oral Mini Oral session 1: Non-metastatic NSCLC

Saturday 18 October 2025

17:15-17:20 CEST

Gastrointestinal cancer Tecentriq   (IIS: NCI, Alliance)**

Clinical outcome of patients (pts) with sporadic vs Lynch syndrome-related stage III colon carcinoma (CC) with deficient mismatch repair (dMMR) treated in a randomized trial of adjuvant FOLFOX alone or combined with atezolizumab (atezo; anti-PD-L1) #752P poster Poster session: Colorectal cancer

Sunday 19 October 2025

Divarasib Single-agent divarasib experience in patients with KRAS G12C-positive pancreatic adenocarcinoma (panc), cholangiocarcinoma (cholangio), and other solid tumors #927MO mini oral Mini oral session: Developmental therapeutics

Friday 17 October 2025

17:00-17:05 CEST

* Investigator Initiated Study (IIS). The study is sponsored by MEDSIR and supported by Genentech, a member of the Roche Group.
** Investigator Initiated Study (IIS). The study is sponsored by the National Cancer Institute (NCI), conducted by the Alliance for Clinical Trials in Oncology and supported by Genentech, a member of the Roche Group.

About Roche in oncology
For over 60 years, Roche has delivered transformative medicines and diagnostics, redefining the treatment of some of the most challenging cancers. Driven by a vision of a future where cancer can be cured, we focus our efforts on cancers with the highest societal impact and where we bring deep expertise, including breast, lung, and blood cancers, while pursuing breakthrough innovation in other areas of unmet need. Our pipeline features a diverse array of modalities, from small molecules and antibodies to next-generation ADCs and allogeneic CAR T-cell therapies. By advancing best-in-class precision medicine, pioneering novel combinations, and leveraging key technologies and partnerships, Roche tackles oncology's toughest challenges with the goal of delivering life-changing outcomes for people with cancer.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Mayer E, et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #LBA16.
[2] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) [Internet; cited 2025 October]. Available from: https://clinicaltrials.gov/study/NCT05306340.
[3] Roche. Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer [Internet; cited 2025 October]. Available from: https://www.roche.com/media/releases/med-cor-2025-09-22.
[4] Powles T, et al. IMvigor011: a phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #LBA8.
[5] Natera. IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit [Internet; cited 2025 October]. Available from: https://www.natera.com/company/news/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit/https://www.natera.com/company/news/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit/.
[6] Mok T, et al. Final overall survival (OS) and safety analysis of the phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC). To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #LBA73.
[7] Peters S, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(9); 829-838.
[8] Mok T, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056-1064.
[9] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v.5.2024.
[10] Dziadziuszko R, et al. Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC). To be presented at: ESMO Congress; 2025 Oct 17-21; Berlin, Germany. Abstract #1787MO.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Hans Trees, PhD
Phone: +41 79 407 72 58 Sileia Urech
Phone: +41 79 935 81 48 Nathalie Altermatt
Phone: +41 79 771 05 25 Lorena Corfas
Phone: +41 79 568 24 95 Simon Goldsborough
Phone: +44 797 32 72 915 Karsten Kleine
Phone: +41 79 461 86 83 Kirti Pandey
Phone: +49 172 6367262 Yvette Petillon
Phone: +41 79 961 92 50 Dr Rebekka Schnell
Phone: +41 79 205 27 03   Roche Investor Relations

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected] Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected] Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]   Investor Relations North America

Media & Investor Release ESMO 2025 Curtain Raiser English

Attachments

Media & Investor Release ESMO 2025 Curtain Raiser English...

SummaryMirion Technologies is rated a buy, supported by strong nuclear power demand and a robust, recurring revenue model.The Paragon acquisition doubles MIR's SMR exposure, enhances its product portfolio, and strengthens its position in next-generation nuclear technology.MIR targets 30% EBITDA margins by 2028, driven by operating leverage, business mix shift, and operational restructuring.Valuation supports ~20% upside, with multi-decade nuclear tailwinds and Paragon integration providing clear growth visibility and margin expansion. Monty Rakusen/DigitalVision via Getty Images

Investment Action I give a buy rating for Mirion Technologies (NYSE:MIR) as I see a long, structural growth runway ahead, driven by the global nuclear power demand. The combination of a powerful demand tailwind, a strong market

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Bitcoin’s (CRYPTO: BTC) flash crash late Friday, which happened outside of regular trading hours, has reignited debate about the operating hours of spot BTC exchange-traded funds, particularly the iShares Bitcoin Trust ETF (NASDAQ:IBIT).

The apex cryptocurrency collapsed from $116,000 to under $110,000 within minutes after President Donald Trump threatened 100% tariffs on China in response to “aggressive stance” on export controls.

The sudden spike caught traders off-guard, triggering over $19 billion in liquidations, the largest single-day wipeout in cryptocurrency history.”

See Also: Bitcoin (BTC) Price Predictions: 2025, 2026, 2030

ETF Investors Left In The Lurch?The crash fueled concerns about the lack of 24/7 trading of BTC exchange-traded funds, which have become a popular vehicle for institutional investors, Forbes reported, quoting Tommy Doyle, global head of client management at Xapo Bank.

"The extreme volatility in the price of Bitcoin overnight highlights why institutional investors increasingly view access to 24/7 liquidity as essential to prudent risk management,” Doyle said.

Notably, these ETFs, including the nearly $100 billion IBIT, are bound by stock trading hours, which prevents investors from responding to weekend price shifts.

“Whilst Bitcoin ETFs remain bound by traditional market trading hours, institutional investors with direct bitcoin accounts can continue to access liquidity and risk manage their bitcoin exposure throughout the weekend, especially relevant amid recent seismic price moves,” Doyle told Forbes.

It’s worth noting that Robinhood allows trading from 8 p.m. ET on Sunday until 8 p.m. ET on Friday, with some restrictions.

BlackRock’s IBIT ETF is the largest cryptocurrency-based investment fund currently in operation, with assets under management totaling almost $94 billion, according to SoSo Value.

Overall, BTC ETFs reported net inflows exceeding $2.70 billion for the week ended Oct.10.

Price Action: At the time of writing, BTC was trading at $115,645.17, rebounding 4.33% in the last 24 hours, according to data from Benzinga Pro.

IBIT shares closed 3.74% lower at $66.17 during Friday’s regular trading session. Year-to-date, the stock has gained 24%.

Benzinga’s proprietary Edge Rankings show Momentum as the strongest category for IBIT at 88.34/100. To see how IBIT stock ranks for Value, Growth and Quality, click here.

Read Next: 

Weekend Roundup: Bitcoin Jesus’ Tax Evasion Case, Gold’s Rally And More Crypto News
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Photo Courtesy: Arsenii Palivoda on Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.